Flow For B ALL MRD

The B-ALL MRD test analyzes and quantifies the residual leukemic cells in the bone marrow or peripheral blood.

• To assess the presence and level of minimal residual disease (MRD) in patients with B-ALL • To evaluate treatment effectiveness • To monitor disease progression and relapse risk • To guide treatment decisions, such as the need for further therapy or stem cell transplantation

The B-ALL MRD test is typically recommended for individuals who have been diagnosed with B-ALL. Patients who may benefit from this test include • those undergoing treatment for B-ALL, • individuals who have completed treatment to assess their response, and • patients at risk of relapse or with suspected disease recurrence.

Abnormal results indicating a high level of MRD may suggest a higher risk of relapse or insufficient response to treatment.

During the test, a sample of bone marrow will be collected using a needle. The sample will then be sent to the laboratory for analysis using flow cytometry.

• Inform your doctor about any medications or supplements you are taking. Also, tell them if you have any specific requirements. • Follow any dietary instructions provided by your doctor.

• Complete Blood Count (CBC): Helps evaluate overall blood cell count and health • Bone Marrow Aspiration and Biopsy: Provides detailed information about the structure and function of bone marrow cells • Cytogenetic Testing: Identifies specific genetic changes or abnormalities in cancer cells

Minimal Residual Disease test for B-Cell Acute Lymphoblastic Leukaemia

B-Cell Acute Lymphoblastic Leukaemia is a type of blood cancer that affects the white blood cells, specifically B-cells. It is characterised by the rapid production of immature lymphoblasts in the bone marrow, which overcrowd normal blood cells and impair their normal function.